GLUE vs. NTLA, PGEN, ZYME, STOK, SION, SYRE, CRMD, VERV, CRON, and PRAX
Should you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Intellia Therapeutics (NTLA), Precigen (PGEN), Zymeworks (ZYME), Stoke Therapeutics (STOK), Sionna Therapeutics (SION), Spyre Therapeutics (SYRE), CorMedix (CRMD), Verve Therapeutics (VERV), Cronos Group (CRON), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.
Monte Rosa Therapeutics vs. Its Competitors
Monte Rosa Therapeutics (NASDAQ:GLUE) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.
Monte Rosa Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.31, meaning that its stock price is 131% more volatile than the S&P 500.
In the previous week, Intellia Therapeutics had 6 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 6 mentions for Intellia Therapeutics and 0 mentions for Monte Rosa Therapeutics. Intellia Therapeutics' average media sentiment score of 1.23 beat Monte Rosa Therapeutics' score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the news media.
80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 6.5% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 3.1% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Monte Rosa Therapeutics has a net margin of 13.58% compared to Intellia Therapeutics' net margin of -908.48%. Monte Rosa Therapeutics' return on equity of 9.95% beat Intellia Therapeutics' return on equity.
Monte Rosa Therapeutics presently has a consensus price target of $15.33, suggesting a potential upside of 227.64%. Intellia Therapeutics has a consensus price target of $29.05, suggesting a potential upside of 155.86%. Given Monte Rosa Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Monte Rosa Therapeutics is more favorable than Intellia Therapeutics.
Monte Rosa Therapeutics has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Monte Rosa Therapeutics beats Intellia Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Monte Rosa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monte Rosa Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:GLUE) was last updated on 8/26/2025 by MarketBeat.com Staff
MarketBeat All Access